IPO registrations (S-1, F-1) · Registrants
Phio Pharmaceuticals Corp.
- SEC CIK
- 1533040 · filings on EDGAR ↗
- Former names
- RXi Pharmaceuticals Corp (2011–2018)
- Registration
- Form S-1, first filed 2011-10-25, last 2025-01-21; 20 initial registrations, 20 amendments
- Outcome
- Final prospectus filed 2015-05-29; declared effective 2012-02-14; withdrawal requested 2024-05-20
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 411 SWEDELAND ROAD, SUITE 23-1080, King Of Prussia, PA 19406
- EIN
- 45-3215903
- Ticker
- PHIO (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Phio Pharmaceuticals Corp. on the corporate pages
On this site
- Business registration: Phio Pharmaceuticals Corp. Fuzzy (name and state)
- Form 5500 plan sponsor: RXI PHARMACEUTICALS CORPORATION EXACT (EIN (EXACT))
- Form D issuer: Phio Pharmaceuticals Corp. EXACT (CIK (EXACT))
- SEC filer: Phio Pharmaceuticals Corp. EXACT (CIK (EXACT))
- Person page: Robert L Ferrara Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 75
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2011-10-25 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0000950123-11-091680 ↗ |
| 2011-12-08 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0000950123-11-102498 ↗ |
| 2011-12-29 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0000950123-11-104538 ↗ |
| 2012-01-23 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0000950123-12-001079 ↗ |
| 2012-02-07 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0000950123-12-002130 ↗ |
| 2012-02-13 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0000950123-12-002294 ↗ |
| 2012-02-14 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0000950123-12-002472 ↗ |
| 2012-02-14 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-12-000489 ↗ |
| 2012-05-18 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0001193125-12-240024 ↗ |
| 2012-07-06 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-12-002091 ↗ |
| 2013-05-10 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0001193125-13-214347 ↗ |
| 2013-07-26 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001193125-13-304770 ↗ |
| 2013-08-08 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-13-002352 ↗ |
| 2013-09-18 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0001193125-13-370444 ↗ |
| 2013-09-30 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-13-002832 ↗ |
| 2014-04-18 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-14-001058 ↗ |
| 2015-04-13 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0001193125-15-127716 ↗ |
| 2015-05-21 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001193125-15-195466 ↗ |
| 2015-05-22 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001193125-15-197416 ↗ |
| 2015-05-27 | S-1MEF | S-1MEF (added securities) | RXi Pharmaceuticals Corp | 0001193125-15-202411 ↗ |
| 2015-05-27 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-15-001462 ↗ |
| 2015-05-29 | 424B4 | 424B4 (final prospectus) | RXi Pharmaceuticals Corp | 0001193125-15-206742 ↗ |
| 2016-10-21 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0001193125-16-743993 ↗ |
| 2016-11-14 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001193125-16-766243 ↗ |
| 2016-11-30 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001193125-16-779953 ↗ |
| 2016-12-14 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001193125-16-792793 ↗ |
| 2016-12-15 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001193125-16-793785 ↗ |
| 2016-12-15 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-16-006458 ↗ |
| 2016-12-19 | 424B4 | 424B4 (final prospectus) | RXi Pharmaceuticals Corp | 0001193125-16-796197 ↗ |
| 2017-05-09 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-17-001227 ↗ |
| 2017-06-21 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-17-001608 ↗ |
| 2017-07-14 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0001193125-17-228636 ↗ |
| 2017-07-31 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001193125-17-242561 ↗ |
| 2017-08-08 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-17-002061 ↗ |
| 2017-08-18 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0001193125-17-262349 ↗ |
| 2017-08-30 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-17-002233 ↗ |
| 2018-04-06 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-18-000779 ↗ |
| 2018-05-09 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0001193125-18-157718 ↗ |
| 2018-05-31 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-18-001392 ↗ |
| 2018-08-31 | S-1 | S-1 (registration) | RXi Pharmaceuticals Corp | 0001683168-18-002585 ↗ |
| 2018-09-14 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001683168-18-002758 ↗ |
| 2018-09-28 | S-1/A | S-1/A (amendment) | RXi Pharmaceuticals Corp | 0001683168-18-002882 ↗ |
| 2018-09-28 | EFFECT | EFFECT (declared effective) | RXi Pharmaceuticals Corp | 9999999995-18-002504 ↗ |
| 2018-10-01 | S-1MEF | S-1MEF (added securities) | RXi Pharmaceuticals Corp | 0001683168-18-002897 ↗ |
| 2018-10-02 | 424B4 | 424B4 (final prospectus) | RXi Pharmaceuticals Corp | 0001683168-18-002919 ↗ |
| 2019-08-30 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-19-002795 ↗ |
| 2019-09-25 | S-1/A | S-1/A (amendment) | Phio Pharmaceuticals Corp. | 0001683168-19-003041 ↗ |
| 2019-10-01 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-19-003116 ↗ |
| 2019-10-01 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-19-002218 ↗ |
| 2020-01-31 | S-1/A | S-1/A (amendment) | Phio Pharmaceuticals Corp. | 0001683168-20-000317 ↗ |
| 2020-02-07 | S-1/A | S-1/A (amendment) | Phio Pharmaceuticals Corp. | 0001683168-20-000390 ↗ |
| 2020-02-11 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-20-000314 ↗ |
| 2020-02-12 | 424B4 | 424B4 (final prospectus) | Phio Pharmaceuticals Corp. | 0001683168-20-000451 ↗ |
| 2020-05-12 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-20-001524 ↗ |
| 2020-05-28 | S-1/A | S-1/A (amendment) | Phio Pharmaceuticals Corp. | 0001683168-20-001772 ↗ |
| 2020-06-01 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-20-001301 ↗ |
| 2020-07-09 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-20-002231 ↗ |
| 2020-07-17 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-20-001854 ↗ |
| 2021-02-08 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-21-000508 ↗ |
| 2021-05-21 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-21-002069 ↗ |
| 2023-04-28 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-23-002765 ↗ |
| 2023-05-09 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-23-001352 ↗ |
| 2023-06-08 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-23-004016 ↗ |
| 2023-06-16 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-23-001782 ↗ |
| 2023-12-19 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-23-008964 ↗ |
| 2023-12-27 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-23-003764 ↗ |
| 2024-05-17 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-24-003624 ↗ |
| 2024-05-20 | RW | RW (withdrawal request) | Phio Pharmaceuticals Corp. | 0001683168-24-003696 ↗ |
| 2024-07-01 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-24-002034 ↗ |
| 2024-07-26 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-24-005092 ↗ |
| 2024-08-01 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-24-002365 ↗ |
| 2025-01-21 | S-1 | S-1 (registration) | Phio Pharmaceuticals Corp. | 0001683168-25-000460 ↗ |
| 2025-01-28 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-25-000224 ↗ |
| 2025-08-22 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-25-002730 ↗ |
| 2025-12-03 | EFFECT | EFFECT (declared effective) | Phio Pharmaceuticals Corp. | 9999999995-25-003514 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bitterman Robert J | Director; Director,Officer | Chairman, Pres & CEO; Chairman, Pres. & CEO; Interim Executive Chairman; President & CEO | 43 | 2013–2026 | |
| Brownlie Keith L | Director | 8 | 2013–2019 | ||
| CAUWENBERGH GEERT | Director; Director,Officer | Chief Executive Officer; President and CEO; President & CEO | 85 | 2013–2023 | |
| Galena Biopharma, Inc. | TenPercentOwner | 2 | 2013 | ||
| Kontulis Caitlin | Officer | Secretary and Controller; Secretary & Controller; Secretary & Dir. of Finance; Secretary & Sr. Dir. Finance; Secretary & VP Finance & Admin | 18 | 2013–2024 | |
| Pavco Pamela | Officer | Chief Development Officer | 9 | 2013–2017 | |
| Opko Health, Inc. | TenPercentOwner | 1 | 2013 | ||
| Advanced RNA Technologies, LLC | Other; TenPercentOwner | 15 | 2013–2014 | ||
| Dorman H. Paul | Director | 12 | 2013–2022 | ||
| Lockshin Curtis | Director | 17 | 2013–2026 | ||
| Eliseev Alexey | Officer | Chief Business Officer | 5 | 2017 | |
| Dispersyn Gerrit | Director,Officer; Officer | Chief Development Officer; President & CEO; President & COO | 15 | 2017–2022 | |
| Freeman Jonathan E | Director | 10 | 2017–2026 | ||
| Barrett John A | Officer | Chief Development Officer | 2 | 2019 | |
| Ferrara Robert L | Director | 13 | 2019–2025 | person page Fuzzy | |
| BRADFORD PATRICIA A | Director | 8 | 2022–2026 | ||
| Infarinato Robert M. | Officer | VP, CFO; VP, Chief Financial Officer | 3 | 2024 | |
| Deming David H | Director | 3 | 2025–2026 | ||
| Carson Lisa Cabott | Officer | Chief Financial Officer; VP, Finance and Administration | 5 | 2025–2026 | |
| Plott Ronald Todd | Director | 4 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-11-12 | Phio Pharmaceuticals Corp. | Biotechnology | $25,931,342 | $1,415,796 | 5 | 1 |
| 2025-08-04 | Phio Pharmaceuticals Corp. | Biotechnology | $5,080,826 | $232,149 | 2 | 1 |
| 2025-01-28 | Phio Pharmaceuticals Corp. | Biotechnology | $3,660,000 | $152,500 | 4 | 1 |
| 2025-01-28 | Phio Pharmaceuticals Corp. | Biotechnology | $6,382,020 | $265,918 | 4 | 1 |
| 2025-01-28 | Phio Pharmaceuticals Corp. | Biotechnology | $5,000,010 | $208,334 | 4 | 1 |
| 2025-01-07 | Phio Pharmaceuticals Corp. | Biotechnology | $480,000 | $30,000 | 4 | 1 |
| 2025-01-03 | Phio Pharmaceuticals Corp. | Biotechnology | $1,314,650 | $54,649 | 4 | 1 |
| 2024-07-24 | Phio Pharmaceuticals Corp. | Biotechnology | $6,358,543 | $136,322 | 8 | 1 |
| 2023-12-19 | Phio Pharmaceuticals Corp. | Biotechnology | $5,399,124 | $532,563 | 4 | 1 |
| 2023-06-13 | Phio Pharmaceuticals Corp. | Biotechnology | $10,907,728 | $2,999,373 | 3 | 1 |
| 2023-05-02 | Phio Pharmaceuticals Corp. | Biotechnology | $4,010,519 | $4,010,519 | 3 | 1 |
| 2022-11-23 | Phio Pharmaceuticals Corp. | Biotechnology | $1,750 | $1,750 | 1 | 1 |
| 2021-02-16 | Phio Pharmaceuticals Corp. | Pharmaceuticals | $24,264,137 | $14,001,909 | 14 | 1 |
| 2020-04-14 | Phio Pharmaceuticals Corp. | Pharmaceuticals | $4,375,011 | $4,375,011 | 10 | 1 |
| 2020-02-24 | Phio Pharmaceuticals Corp. | Pharmaceuticals | $1,903,128 | $1,903,128 | 6 | 1 |
| 2017-08-18 | RXi Pharmaceuticals Corp | Pharmaceuticals | $15,261,000 | $1,937,904 | 1 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.